September 1, 2026

A Message to Patients and Care Providers:

For nearly a century, healthcare providers have relied on Baxter to help deliver patient care, and we do not take that responsibility lightly. Guided by our Mission to Save and Sustain Lives, patient safety and product quality are at the center of everything we do.

As part of our commitment to patient safety, Baxter maintains rigorous quality and testing processes and continues to invest in enhanced detection and monitoring capabilities, including particulate testing of products using filtration and microscopic analysis. Through these processes, we identified the potential for particulate matter in four specific lots of distributed products. We voluntarily recalled the affected batches and are investigating potential root causes.

Importantly, as of Sep. 1, 2026, Baxter has not received any reports of adverse events associated with these specific lots. In coordination with the U.S. Food and Drug Administration (FDA), Baxter initiated recalls for the impacted lots of 0.9% Sodium Chloride Injection and 70% Dextrose Injection on Aug. 17, 2026, and Anticoagulant Sodium Citrate Solution on Aug. 19, 2026, respectively. Customers who received the affected products were notified and instructed to immediately locate, isolate, and discontinue use of the affected lot numbers.

We understand that product recalls can raise questions. Baxter supports the use of increasingly sophisticated testing and monitoring technologies that provide greater visibility into product quality and help manufacturers identify potential issues earlier and with greater precision. The recall notices describe the potential presence of particulate matter that was identified through these enhanced testing and monitoring capabilities.

A serious adverse event would be most likely to occur at or shortly after the time of infusion. If you are a patient with questions or concerns about your care, please speak with your healthcare provider. Healthcare providers and customers with questions about the affected lots or recall process may contact Baxter Customer Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Customers with clinical questions may contact MedInfo@baxter.com.

Baxter will continue to monitor this matter and work closely with the FDA as appropriate. We remain committed to transparency, patient safety, and providing our customers with the information they need to continue delivering care with confidence.